Stem Cell Transplantation for Multiple Myeloma: Current and Future Status
Open Access
- 10 December 2011
- journal article
- review article
- Published by American Society of Hematology in Hematology
- Vol. 2011 (1), 191-196
- https://doi.org/10.1182/asheducation-2011.1.191
Abstract
High-dose melphalan with autologous stem cell support has been an integral part of myeloma therapy for more than 25 years, either as salvage therapy or as consolidation of an initial remission. Although multiple phase 3 trials have demonstrated that this therapy results in higher response rates and longer remission times than conventional chemotherapy, the use of thalidomide, lenalidomide, and bortezomib as induction therapy has limited the clinical relevance of these trials. Moreover, ongoing trials have shown that initial induction therapy may affect transplantation outcome, and that long-term disease control can be achieved in a substantial number of patients with a variety of posttransplantation maintenance therapies. This article summarizes the results of ongoing and recently published clinical trials and describes how they have affected current transplantation recommendations.Keywords
This publication has 36 references indexed in Scilit:
- International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationBlood, 2011
- Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III TrialJournal of Clinical Oncology, 2010
- International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocolsCancer, 2010
- Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapyBlood, 2010
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myelomaBlood, 2010
- Reiterative Survival Analyses of Total Therapy 2 for Multiple Myeloma Elucidate Follow-Up Time Dependency of Prognostic Variables and Treatment ArmsJournal of Clinical Oncology, 2010
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialThe Lancet Oncology, 2010
- Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321Journal of Clinical Oncology, 2006
- High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMABlood, 2005
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaThe New England Journal of Medicine, 2003